December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

488.66 +1.41 (+0.29%)
Streaming Delayed Price Updated: 10:16 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
News headline image
United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%. 
Via StockStory
Topics Stocks
News headline image
How Is The Market Feeling About United Therapeutics? ↗
 
Via Benzinga
News headline image
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About United Therapeutics? ↗
 
Via Benzinga
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
From United Therapeutics Corporation
Via Business Wire
News headline image
Earnings Outlook For United Therapeutics ↗
 
Via Benzinga
News headline image
Decoding 7 Analyst Evaluations For United Therapeutics ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 7 Takes On United Therapeutics ↗
 
Via Benzinga
News headline image
$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Announces Successful World’s First UKidney Transplant
From United Therapeutics Corporation
Via Business Wire
News headline image
Peering Into United Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
A Look Into United Therapeutics Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Key Takeaways From United Therapeutics Analyst Ratings ↗
 
Via Benzinga
News headline image
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
From United Therapeutics Corporation
Via Business Wire
News headline image
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
News headline image
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
News headline image
U.S. Stock: United Therapeutics Corp ↗
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. 
Via Talk Markets
News headline image
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.